Navigation Links
Blutkrankheiten: Europäische Hämatologen kommen vom 13. bis zum 16. Juni 2013 in Stockholm zusammen
Date:3/4/2013

AMSTERDAM, March 4, 2013 /PRNewswire/ --

- Einladung zum 18. Jahreskongress der EHA (European Hematology Association)

Der Vorstand der European Hematology Association (EHA) freut sich, Sie als Pressevertreter herzlich zum 18.EHA-Kongress einladen zu dürfen.

Über 9.500 Mitglieder aus der ganzen Welt werden zum 18. Kongress der European Hematology Association auf der Stockholmsmässan in Stockholm (Schweden) erwartet, der vom 13. bis zum 16. Juni 2013 stattfindet.

Informationen zum EHA-Jahreskongress

Die Hämatologie ist ein Spezialgebiet der Medizin, das sich mit allen Aspekten rund um das Thema Blut befasst: seinem Ursprung im Knochenmark, mit Blutkrankheiten und mit deren Behandlung. Dabei werden die neuesten Daten zur Forschung und Entwicklung im Bereich der Hämatologie vorgestellt. Der Kongress richtet sich an Experten, die im Bereich Hämatologie tätig sind oder sich dafür interessieren. Die wissenschaftlichen Themen reichen von der Stammzellenphysiologie und -Entwicklung über Leukämie; Lymphome; Diagnose und Behandlung; rote Blutkörperchen; Erkrankungen der weißen Blutkörperchen und der Blutplättchen; Hämophilie und Myelom; Thrombose und Blutgerinnungsstörungen sowie Transfusionen und Stammzellentransplantation.

Diverse Sitzungen des Kongressprogramms befassen sich mit allgemeineren Gesundheitsthemen:

Die Sitzung mit dem Schwerpunkt Patientenanwaltschaft beleuchtet das Thema Personalisierte Medizin aus unterschiedlichen Perspektiven;

Das gemeinsame Symposium der EHA und der ASH (American Society of Hematology) beschäftigt sich mit dem Thema Gesundheitsdienstleistungen in Zeiten der Wirtschaftskrise. Anlässlich des gemeinsamen Symposiums der EHA der ESH widmen sich Hämatologen und P
'/>"/>

SOURCE European Hematology Association
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Maladies du sang : congrès des hématologues européens à Stockholm, du 13 au 16 juin 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... ALBANY, New York , May 21, 2013 /PRNewswire/ ... published by Transparency Market Research ( http://www.transparencymarketresearch.com ) "Biochip ... Science Research, IVD Tests) - U.S. Industry Analysis, Size, Share, ... USD 2.4 billion in 2011 and is expected to ... 2018, to reach an estimated value of USD 4.7 ...
(Date:5/21/2013)... 2013 Many have long discussed the ... acne. Recently physicians from Clinical Psychiatry.com readdressed ... the skin, and suggested using hypnotherapy and ... produced from stress that cause acne. , Doctors in ... acne brings about, stress causes changes in the skin ...
(Date:5/21/2013)... May 21, 2013  MacroGenics, Inc. today announced ... margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), ... HER2 oncoprotein," will be presented at the 2013 ... Oncology during the Developmental Therapeutics - Immunotherapy Oral ... – 4:30 PM.  The presentation will describe the ...
(Date:5/21/2013)... 21, 2013  Personal Genome Diagnostics Inc. (PGDx), ... methodologies and expertise in genomic analysis of defined ... collaboration with Blueprint Medicines.  PGDx is an innovator ... alterations in tumors, and Blueprint Medicines is an ... a genetically defined patient population. "This ...
Breaking Biology Technology:The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 2The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 4The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 5Adult Acne Treatment, Probiotic Action Explains How Hypnotherapy and Probiotics May Cure Various Skin Conditions 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 2Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 3
... Microtest Laboratories,( http://www.microtestlabs.com ) has doubled ... purchase of an additional MicroSeq(R),Microbial Identification System., ... sequence-based system that,enables Microtest technicians to more ... not viable or easily identified., "With ...
... June 3 VIA Pharmaceuticals,(Nasdaq: VIAP ), ... for the treatment of cardiovascular disease, announced today ... officer of VIA, and,James G. Stewart, senior vice ... update at the Seventh Annual Needham & Company,Biotechnology ...
... and ... Agriculture Conference, ROME, June 3 More can be done ... help address the,strong and growing global demand for grain, Mike Gumina, vice ... Nations Food and,Agriculture Organization Conference being held here today., "Improved farming ...
Cached Biology Technology:Microtest Labs Doubles Microbial Identification, Analytical Services 2More Can Be Done Now to Address the Growing Global Demand for Grain 2More Can Be Done Now to Address the Growing Global Demand for Grain 3
(Date:5/21/2013)... Michigan Water Center today awarded 12 research grants, ... and protection efforts. , The two-year grants of ... efforts to track the remediation of harmful algae ... non-native weedy plant invasions; study chromosomal damage in ... restoration activities. , The grants were awarded to ...
(Date:5/21/2013)... decades, scientists have developed many devices that can reopen ... generally effective, each of these treatments has drawbacks, including ... from MIT analyzes the potential usefulness of a new ... drug-releasing stents, but may pose fewer risks. With this ... for only a brief period, during which it releases ...
(Date:5/20/2013)... also commonly resistant to antimicrobial substances made by ... mBio , the online open-access journal of ... and host antimicrobials LL-37 and lysozyme, which help ... that patients with life-threatening multi-drug resistant infections are ... is a last-line drug for treating several kinds ...
Breaking Biology News(10 mins):U-M Water Center awards $570K in Great Lakes restoration grants 2U-M Water Center awards $570K in Great Lakes restoration grants 3U-M Water Center awards $570K in Great Lakes restoration grants 4Evaluating a new way to open clogged arteries 2Evaluating a new way to open clogged arteries 3Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3
... ,Rewilding with taxon substitutes, the intentional introduction of ... the loss of recently extinct species, is highly controversial, ... In a paper published today in Current ... Sciences and colleagues present the first empirical evidence that ...
... they tell of their former lives, these old bones ... And now, geologists have found, they tell of the ... evolutionary ecology of ancient sirenians--commonly known as sea cows--scientist ... could change the view of climate during the Eocene ...
... you belong to the one-half of the population that frequently ... good for you? Well, according to a study ... a journal of the Association for Psychological Science, there seems ... dietary supplement use and the health status of individuals. Wen-Bin ...
Cached Biology News:Giant tortoises show rewilding can work 2Fossil sirenians give scientists new look at ancient climate 2Are dietary supplements working against you? 2
... Chicken polyclonal to Opsin 1 ( Abpromise ... Synthetic peptide: YEDSTHASIFTYT, corresponding to amino acids ... synthetic peptide corresponding to amino acids 18/30 of ... used as immunogen. Entrez Gene ...
EnzChek Ultra Xylanase Assay Kit *500 assays*...
Anti-DAP-1, Rabbit Monoclonal Immunogen: KLH-conjugated synthetic peptide corresponding to the C-terminal region of human DAP-1. Molecular Weight: 11 kDa Quality Assurance: Routinely eval...
Wnt-1 (G-19)...
Biology Products: